The efficacy of γ-aminobutyric acid type A receptor (GABA

Animals Behavior, Animal / drug effects Bridged-Ring Compounds Convulsants GABA Modulators / pharmacology Hypnotics and Sedatives / pharmacology Larva Locomotion / drug effects Midazolam / pharmacology Protein Subunits / genetics Receptors, GABA-A / genetics Seizures / chemically induced Zebrafish
Benzodiazepine Chemical Threat Agent GABA(A)R Seizures Tetramethylenedisulfotetramine Zebrafish

Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 30 03 2021
revised: 02 07 2021
accepted: 05 07 2021
pubmed: 16 7 2021
medline: 7 8 2021
entrez: 15 7 2021
Statut: ppublish

Résumé

The chemical threat agent tetramethylenedisulfotetramine (TETS) is a γ-aminobutyric acid type A receptor (GABA

Identifiants

DOI: 10.1016/j.taap.2021.115643 PMID: 34265354 PMC: PMC8514104
pubmed: 34265354
pii: S0041-008X(21)00247-7
doi: 10.1016/j.taap.2021.115643
pmc: PMC8514104
mid: NIHMS1745152
pii:
doi:

Substances chimiques

Bridged-Ring Compounds 0
Convulsants 0
GABA Modulators 0
Hypnotics and Sedatives 0
Protein Subunits 0
Receptors, GABA-A 0
tetramethylenedisulfotetramine F6TS3WME05
Midazolam R60L0SM5BC

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115643

Subventions

Organisme : NINDS NIH HHS
ID : R21 NS072094
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS110647
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS079202
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

J Toxicol Clin Toxicol. 2004;42(2):209-16
pubmed: 15214628
J Pharmacol Exp Ther. 2005 Jun;313(3):1118-25
pubmed: 15687371
Sci Rep. 2016 Jun 27;6:28674
pubmed: 27346730
Mol Pharmacol. 2021 Jan;99(1):78-91
pubmed: 33109687
Hum Genet. 2012 Jun;131(6):977-1008
pubmed: 22207143
Mol Pharmacol. 2003 Feb;63(2):289-96
pubmed: 12527800
Nat Neurosci. 2000 Jun;3(6):587-92
pubmed: 10816315
Nature. 1999 Oct 21;401(6755):796-800
pubmed: 10548105
J Neurophysiol. 2011 Oct;106(4):2057-64
pubmed: 21795619
Arch Toxicol. 2018 Feb;92(2):833-844
pubmed: 29038840
BMC Public Health. 2014 Aug 13;14:842
pubmed: 25115223
Br J Anaesth. 2019 Aug;123(2):e194-e203
pubmed: 30915991
Neuropharmacology. 2009 Jan;56(1):182-9
pubmed: 18762200
Neuropharmacology. 2009 Jan;56(1):141-8
pubmed: 18760291
Nature. 2019 Jan;565(7740):454-459
pubmed: 30602790
Sci Rep. 2021 Mar 18;11(1):6242
pubmed: 33737538
Curr Top Dev Biol. 2019;134:119-149
pubmed: 30999973
J Toxicol Clin Toxicol. 2003;41(7):991-4
pubmed: 14705847
Neuroscience. 2017 Feb 20;343:300-321
pubmed: 27453477
Adv Pharmacol. 2015;73:167-202
pubmed: 25637441
J Med Chem. 2009 Jun 25;52(12):3723-34
pubmed: 19469479
Neurotoxicology. 2009 Jan;30(1):52-8
pubmed: 18952124
Nat Rev Drug Discov. 2011 Jul 29;10(9):685-97
pubmed: 21799515
Front Pharmacol. 2019 Oct 29;10:1222
pubmed: 31736746
Neuropsychopharmacology. 1999 Mar;20(3):255-62
pubmed: 10063485
CNS Drug Rev. 2003 Spring;9(1):3-20
pubmed: 12595909
Toxicol Sci. 2019 Jan 1;167(1):77-91
pubmed: 30364989
Br J Pharmacol. 2013 Mar;168(5):1118-32
pubmed: 23061935
Pharmacol Rev. 2018 Oct;70(4):836-878
pubmed: 30275042
Curr Opin Toxicol. 2020 Oct-Dec;23-24:56-66
pubmed: 32656393
Neurotoxicology. 2020 Jan;76:220-234
pubmed: 31811871
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8607-12
pubmed: 24912155
Biochem Pharmacol. 2004 Oct 15;68(8):1573-80
pubmed: 15451401
Eur J Pharmacol. 2002 Feb 15;437(1-2):31-9
pubmed: 11864636
Neurotoxicology. 2012 Mar;33(2):207-11
pubmed: 22056734
Ann Emerg Med. 2005 Jun;45(6):609-13
pubmed: 15940093
Psicothema. 2006 Feb;18(1):100-4
pubmed: 17296016
Neuroscience. 2005;131(3):759-68
pubmed: 15730879
Nature. 1985 Mar 14-20;314(6007):168-71
pubmed: 2983231
J Biol Chem. 2012 Nov 23;287(48):40224-31
pubmed: 23038269
J Pharmacol Exp Ther. 2010 Mar;332(3):1040-53
pubmed: 19940102
Neurobiol Dis. 2020 Jan;133:104491
pubmed: 31176716
J Pharmacol Exp Ther. 2012 May;341(2):435-46
pubmed: 22328574
PLoS One. 2018 Apr 27;13(4):e0196083
pubmed: 29702678
Curr Treat Options Neurol. 2016 Apr;18(4):18
pubmed: 26923608
Br J Pharmacol. 2013 May;169(2):371-83
pubmed: 23472852
Forensic Sci Int. 2011 Jan 30;204(1-3):e24-7
pubmed: 20678875
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
J Pharmacol Exp Ther. 2013 Oct;347(1):235-41
pubmed: 23902941
Neuropharmacology. 2020 May 15;168:107966
pubmed: 32120063
J Forensic Sci. 2011 Jan;56 Suppl 1:S234-237
pubmed: 21198624
Neurobiol Dis. 2020 Jan;133:104335
pubmed: 30468862
Neurosci Lett. 2004 Jan 23;355(1-2):77-80
pubmed: 14729239
J Pharmacol Exp Ther. 2008 Dec;327(3):954-68
pubmed: 18791063
Eur J Pharmacol. 1984 May 18;101(1-2):127-34
pubmed: 6086357

Auteurs

Paige C Mundy (PC)

Department of Molecular Biosciences, University of California, School of Veterinary Medicine, Davis, CA 95616, United States. Electronic address: pacmundy@ucdavis.edu.

Brandon Pressly (B)

Department of Pharmacology, University of California, School of Medicine, Davis, CA 95616, United States. Electronic address: bpressly@ucdavis.edu.

Dennis R Carty (DR)

Department of Molecular Biosciences, University of California, School of Veterinary Medicine, Davis, CA 95616, United States.

Bianca Yaghoobi (B)

Department of Molecular Biosciences, University of California, School of Veterinary Medicine, Davis, CA 95616, United States. Electronic address: byaghoobi@ucdavis.edu.

Heike Wulff (H)

Department of Pharmacology, University of California, School of Medicine, Davis, CA 95616, United States. Electronic address: hwulff@ucdavis.edu.

Pamela J Lein (PJ)

Department of Molecular Biosciences, University of California, School of Veterinary Medicine, Davis, CA 95616, United States. Electronic address: pjlein@ucdavis.edu.

Articles similaires

Pulmonary Atelectasis After Sedation With Propofol vs Propofol-Ketamine for Magnetic Resonance Imaging in Children: A Randomized Clinical Trial.

Yu Jeong Bang, Jeayoun Kim, Nam-Su Gil et al.
1.00
Humans Ketamine Propofol Pulmonary Atelectasis Female

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement animal › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Composés polycycliques › Composés pontés › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Stimulants du système nerveux central › Convulsivants › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents GABA › Modulateurs GABA › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Hypnotiques et sédatifs › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Morphogenèse › Métamorphose biologique › Étapes du cycle de vie › Larve › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Locomotion › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzazépines › Benzodiazépines › Midazolam › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Sous-unités de protéines › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs aux acides aminés › Récepteurs GABA › Récepteurs GABA-A › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Crises épileptiques › The efficacy of γ-aminobutyric acid type A...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Poissons › Cypriniformes › Cyprinidae › Danio zébré › The efficacy of γ-aminobutyric acid type A...